Special management of insulin lispro in continuous subcutaneous insulin infusion in young diabetic children: a randomized cross-over study

What Was Tested

This randomized controlled trial paper looks at Insulin Lispro.

Who Took Part

The study group was 27 children.

The age groups tagged for this paper are young children and children, both men and women.

27 very young diabetic children (age 4.6 +/- 2.2 years) treated with CSII participated in an open-label, randomized cross-over multicenter study comparing 2 periods of 16 weeks of CSII with LP or RH.

How the Study Was Run

The researchers set it up as a randomized, open-label, crossover and multicenter study.

The children were allocated by chance, so the Insulin Lispro group and the comparison group should start out alike.

Being open-label, the Insulin Lispro study did not mask who received what.

In the crossover set-up each of the children took both Insulin Lispro and the comparison in turn, acting as their own control.

Running at several centres spread the Insulin Lispro study over different clinics and patient groups.

What Was Measured

The subject headings attached to it are Blood Glucose, Body Mass Index, Diabetes Mellitus, Type 1, Glycated Hemoglobin, Hypoglycemic Agents, Infusion Pumps, Implantable and Insulin.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Insulin Lispro in 27 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2004 (Hormone research), a journal based in Switzerland.

More context: the Insulin Lispro compound page, all human trials.